| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/10/2005 | US20050032808 Pyrazine carboxamide compounds for use in treatment of obesity, psychiatric and neurological disorders; for example, N-(1-piperidinyl)-5,6-diphenyl-2-pyrazinecarboxamide |
| 02/10/2005 | US20050032806 Method for treating anhedonia using dopamine agonists |
| 02/10/2005 | US20050032796 Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis |
| 02/10/2005 | US20050032793 For example, 1,1-dimethylethyl [2-[[2-(diethylamino)-2-oxo-1S-(phenylmethyl)ethyl]amino]-5-methyl-4-oxo-4H-3,1-benzoxazin-6-yl]carbamate; for treating herpes-related disorders |
| 02/10/2005 | US20050032791 Derivatives of sulphonamides, their preparation and use as medicaments |
| 02/10/2005 | US20050032786 1, 3-benzothiazinone derivatives and use thereof |
| 02/10/2005 | US20050032785 LIVER CANCER; ADMINISTERING TAUROLIDINE, direct contact a liver tissue by perfusion in situ, to increase caspase activity in a cell; monitoring the treatment |
| 02/10/2005 | US20050032777 benzyl carbamates and ureas such as 5-(4-(4-cyclopropylmethylpiperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine, used for treatment of sexual disorders |
| 02/10/2005 | US20050032759 administering to humans synergystic mixtures of aromatase inhibitors and epidermal growth factor receptor antagonists as antitumor agents |
| 02/10/2005 | US20050032746 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 02/10/2005 | US20050032736 Immunostimulatory nucleic acid molecules |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032716 controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests on domestic animals; contains a synergistic combination of a A83543 compound and a macrocyclic lactone |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032688 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 02/10/2005 | US20050032682 Contains erythropoietin, which protectively acts on survival of oligodendrocytes, which form myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease |
| 02/10/2005 | US20050032681 Human antithrombin iiis and methods related thereto |
| 02/10/2005 | US20050032214 Cell-specific expression/replication vector |
| 02/10/2005 | US20050032213 Expression vector comprising polynucleotide which codes conditionally-inducible oncogene operably linked to enhancer of a nestin intron for use in prevention and treatment of disease associated with cell loss and/or damage |
| 02/10/2005 | US20050032168 17 human secreted proteins |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032155 Expression vector comprising nucleotide sequences coding defective receptor protein for use as model in treatment and prevention of convulsive disorders |
| 02/10/2005 | US20050032062 Methods for the assessment and prognosis of sarcoidosis |
| 02/10/2005 | US20050032038 Methods of identifying anti-viral agents |
| 02/10/2005 | US20050031674 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 02/10/2005 | US20050031627 Methods for preparing immunoconjugates |
| 02/10/2005 | US20050031613 CD 16 antigen; antibody produced by cell unresistant to lectin which recognizes sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha -bond in a complex N-glycoside-linked sugar chain; signal transduction |
| 02/10/2005 | US20050031604 Secreted by serpent venom glands; endogenous vasopeptidase inhibitors; angiotensin converting enzyme inhibitors; vasodilating and anti-hypertensive action; bradykinins; mass spectrometry |
| 02/10/2005 | US20050031603 Obtainable from whey fraction of milk curd; centrifugation; ultrafiltration; lyophilization |
| 02/10/2005 | US20050031589 Method of treating hepatitis C infection |
| 02/10/2005 | US20050031585 Treating individuals having hepatitis C virus infection, who have failed to respond to therapy with IFN-alpha other than consensus interferon (CIFN), or who, following cessation of therapy with IFN-alpha other than CIFN, have suffered relapse by administering first, then second dosing CIFN, and ribavirin |
| 02/10/2005 | CA2546497A1 Casein hydrolyzate, process for producing the same and use thereof |
| 02/10/2005 | CA2534464A1 Benzoxazepine compound |
| 02/10/2005 | CA2534460A1 Benzylamine derivative |
| 02/10/2005 | CA2532537A1 Biologically non-degradable peptides and their use as angiotensin converting enzyme inhibitors, drugs and functional foods |
| 02/10/2005 | CA2518951A1 Protein kinase inhibitors |
| 02/09/2005 | EP1505074A1 Histamine receptor h3 ordinary activity mutant and utilization thereof |
| 02/09/2005 | EP1505068A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| 02/09/2005 | EP1505067A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism |
| 02/09/2005 | EP1505066A1 Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic |
| 02/09/2005 | EP1505063A1 Benzimidazole derivatives |
| 02/09/2005 | EP1505061A1 Compound exhibiting pgd 2 receptor antagonism |
| 02/09/2005 | EP1504762A1 Medicine for prevention of and treatment for amyloidosis |
| 02/09/2005 | EP1504754A1 Gallocatechin gallate-containing composition |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504010A1 Vitamin-mitomycin conjugates |
| 02/09/2005 | EP1503996A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| 02/09/2005 | EP1503992A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |
| 02/09/2005 | EP1503989A1 Dopamine receptor modulators as antipsychotic agents |
| 02/09/2005 | EP1503988A2 Fredericamycin derivatives |
| 02/09/2005 | EP1503981A2 Substituted tetracycline compounds |
| 02/09/2005 | EP1503803A1 Medicinal formulation in particular for treating herniated invertebral discs |
| 02/09/2005 | EP1503800A1 Treatment and prevention of tissue damage |
| 02/09/2005 | EP1503797A1 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503791A2 Methods of therapy for inducing tolerance |
| 02/09/2005 | EP1503788A2 Treatment of alpha-galactosidase a deficiency |
| 02/09/2005 | EP1503785A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 02/09/2005 | EP1503783A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503769A1 Antibiotic/benzoyl peroxide dispenser |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503765A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 02/09/2005 | EP1503761A1 Substituted piperazines as melanocortin receptor ligands |
| 02/09/2005 | EP1503760A1 Camptothecin derivatives and polymeric conjugates thereof |
| 02/09/2005 | EP1503759A2 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| 02/09/2005 | EP1503754A1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| 02/09/2005 | EP1503752A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy |
| 02/09/2005 | EP1503751A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503746A1 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 02/09/2005 | EP1503735A2 A direct cellular energy delivery system |
| 02/09/2005 | EP1438335A4 Ferroportin-1 mutant |
| 02/09/2005 | EP1436252A4 Hydroxyfattysulfonic acid analogs |
| 02/09/2005 | EP1432436A4 Nutrient therapy for immuno-compromised patients |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1392285B1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 02/09/2005 | EP1390031B1 Topical composition containing a fungicide |
| 02/09/2005 | EP1385854B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 02/09/2005 | EP1370268A4 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 02/09/2005 | EP1349839B1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/09/2005 | EP1313885A4 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 02/09/2005 | EP1287159A4 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| 02/09/2005 | EP1280525B1 Methods and compositions for modulating alpha adrenergic receptor activity |
| 02/09/2005 | EP1274980A4 Solution and crystal structures of mmp-13 active site and uses thereof |
| 02/09/2005 | EP1244640B1 Oxazolidinone derivatives |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |
| 02/09/2005 | EP1184366B1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1098639B1 Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells |
| 02/09/2005 | EP1087951B1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| 02/09/2005 | EP1080104B1 Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme |
| 02/09/2005 | EP1071417B1 Use of cannabidiol as anti-inflammatory agent |
| 02/09/2005 | EP0941093B1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 02/09/2005 | EP0863896B1 Novel imidazole derivatives, method for preparing same, pharmaceutical compositions and use of said derivatives as endothelin antagonists |
| 02/09/2005 | EP0700438B1 Opioid receptors: compositions and methods |